Dave Van den Plas
University of Antwerp
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dave Van den Plas.
International Journal of Pharmaceutics | 2014
Kris Hermans; Dave Van den Plas; Sabina Kerimova; Robert Carleer; Peter Adriaensens; Wim Weyenberg; A. Ludwig
Ocular chitosan films were prepared in order to prolong ocular delivery of cyclosporine A. The mucoadhesive films were prepared using the solvent casting evaporation method. A 2(4) full factorial design was used to evaluate the effect of 4 preparation parameters on the film thickness, swelling index and mechanical properties. Moreover, uniformity of content and in vitro drug release were investigated. Possible interactions between the film excipients were studied by FTIR analysis. In vitro experiments were performed in order to evaluate the cytotoxicity and anti-inflammatory activity of the chitosan films. Film thickness, water uptake, mechanical properties and in vitro release of cyclosporine A were dependent on film composition, especially on the amount of plasticizer. Lower drug release was measured from chitosan films containing a higher amount of plasticizer as glycerol decreased the swelling of chitosan films. FTIR spectra suggest a reorganization of hydrogen bonds between chitosan chains in the presence of glycerol and cyclodextrins. None of the film formulations showed significant cytotoxicity as compared to the negative control using human epithelial cells (HaCaT). Cyclosporine A dispersed in the various film formulations remained anti-inflammatorily active as significant suppression of interleukin-2 secretion in concanavalin A stimulated Jurkat T cells was measured.
European Journal of Dermatology | 2008
Dave Van den Plas; Kris De Smet; Dimitri Lens; Philippe Sollie
In past decades the gold standard for topical burn treatment was the use of silver sulfadiazine. Due to toxicity caused by the silver, the cream base itself, or a combination of both negatively influencing the wound healing process, the healthcare industry searched for alternatives. In recent years, various dressings containing silver have become available to wound professionals. Although these have been reported to be a significant improvement, the dressings still show residual cytotoxicity. Given the ongoing debate about whether and how these dressings influence cell survival, this article endeavours to clarify some of the mystique surrounding the subject. Various commercially available silver-type dressings were analysed in vitro and attention was paid to the cell death stage induced by these dressings on different cell lines. The results show that within 2 hours, for all dressings tested, cells undergo cell death and further analysis suggests that the death stage induced is dependent on the cell line and type of dressing investigated. Further, the antimicrobial activity of all dressings was analysed. The silver dressings tested have potent antimicrobial activity. Our results showed, however, that silver dressings induce rapid cell death of cells involved in wound healing. We therefore recommend the use of silver dressings only on critically contaminated wounds rather than use on a de facto basis.
European Journal of Pharmaceutics and Biopharmaceutics | 2012
Kris Hermans; Dave Van den Plas; Arnout Everaert; Wim Weyenberg; A. Ludwig
Cyclosporine A loaded poly(lactide-co-glycolide) nanoparticles coated with chitosan were prepared using the o/w emulsification solvent evaporation method. A 2(3) full factorial design was used to investigate the effect of 3 preparation parameters on the particle size, polydispersity index, zeta potential and drug release. In vitro experiments were performed in order to evaluate the cytotoxicity and anti-inflammatory activity of the developed nanoparticles. Particle sizes varied from 156 nm to 314 nm, and polydispersity index values of 0.07-0.56 were obtained depending on the different preparation parameters. All nanoparticles showed positive zeta potential values. Nanoparticles prepared with the highest concentration chitosan retained a positive zeta potential after dispersion in simulated lachrymal fluid, which supports the possibility of an electrostatic interaction between these particles and the negatively charged mucus layer at the eye. The in vitro release profile of cyclosporine A from the chitosan-coated nanoparticles was strongly dependent on the release medium used. None of the cationic nanoparticle formulations showed significant cytotoxicity compared to the negative control using human epithelial cells (HaCaT). Cyclosporine A encapsulated in the various nanoparticle formulations remained anti-inflammatory active as significant suppression of interleukine-2 secretion in concanavalin A stimulated Jurkat T cells was observed.
Biology of the Cell | 2004
Dave Van den Plas; Joseph Merregaert
Summry— The Integral membrane protein 2A (Itm2A) is a transmembrane protein belonging to a family composed of at least two other members, Itm2B and Itm2C, all of them having a different expression pattern. The Itm2a gene serves as a marker for early stages in endochondral ossification. In order to understand the role of Itm2A in this process, expression of the gene was investigated in different cell systems. In C3H10T1/2 cells, the gene was upregulated early on when the cells were induced to the chondrogenic lineage but less to the osteogenic lineage. In MCT cells, expression was upregulated at permissive temperatures but not at non‐permissive temperatures. When induced with insulin, ATDC5 cells expressed Itm2a in early stages but not at late stages. Furthermore, PTH treatment seems to upregulate Itm2a transcription.
Biochemical and Biophysical Research Communications | 2003
Dave Van den Plas; Peter Ponsaerts; Viggo Van Tendeloo; Dirk R. Van Bockstaele; Zwi N. Berneman; Joseph Merregaert
Introduction of Cre-recombinase in target cells is currently achieved by transfection of plasmid DNA or by viral-mediated transduction. However, efficiency of non-viral DNA transfection is often low in many cell types, and the use of viral vectors for transduction implies a more complex and laborious manipulation associated with safety issues. We have developed a non-viral non-DNA technique for rapid and highly efficient excision of LoxP-flanked DNA sequences based on electroporation of in vitro transcribed mRNA encoding Cre-recombinase. A K562-DSRed[EGFP] cell line was developed in order to measure Cre-mediated recombination by flow cytometric analysis. These cells have a stable integrated DSRed reporter gene flanked by two LoxP sites, and an EGFP reporter gene, which could only be transcribed when the coding sequence for DSRed was removed. The presented data show recombination efficiencies, as measured by appearance of EGFP-fluorescence, of up to 85% in Cre-recombinase mRNA-electroporated K562-DSRed[EGFP] cells. In conclusion, mRNA electroporation of Cre-recombinase is a powerful, safe, and clinically applicable alternative to current technologies used for excision of stably integrated LoxP-flanked DNA sequences.
Cell Biology International | 2004
Dave Van den Plas; Joseph Merregaert
Integral membrane protein 2A (Itm2A) is a transmembrane protein belonging to a family composed of at least two other members, Itm2B and Itm2C, all of them having a different expression pattern. The protein serves as a marker for early stages in chondrogenesis and T‐cell development. Itm2A is also highly expressed in skeletal muscle. In order to understand the role of Itm2A in muscle development, we constitutively overexpressed exogenous Itm2A in C2C12 myoblast cells. Several clones expressing high levels of Itm2a were isolated and characterized. Overexpression was associated with enhanced tube formation and the appearance of multinuclear cells. Gene expression analysis demonstrated that muscle creatin kinase was upregulated in the presence of exogenous Itm2A. Interestingly, proliferation rates were not altered in the undifferentiated myoblast C2C12 cells. These results demonstrate that overexpression of Itm2a in C2C12 enhances myogenic differentiation in vitro.
International Journal of Pharmaceutics | 2007
Wim Weyenberg; Plamen Filev; Dave Van den Plas; Jo Vandervoort; Kris De Smet; Philippe Sollie; A. Ludwig
Archive | 2006
Dave Van den Plas; Kris De Smet; Philippe Sollie
Archive | 2007
Dave Van den Plas; Kris De Smet; Philippe Sollie
Blood | 2004
Zwi N. Berneman; Jeremy P. Brown; Sjaak van der Sar; Dave Van den Plas; Lena Van den Eeden; Dirk R. Van Bockstaele; Philippe G. Jorens; Viggo Van Tendeloo; Joseph Merregaert; Prim B. Singh; Peter Ponsaerts